Gilead Sciences stock trades 0.32 percent above its Xetra close

Published on 10/18/2026 at 17:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock is EUR 139.28 in weekend trading on October 18, 2026. It is 0.32 percent above Xetra's close EUR 138.84 on October 16, 2026.

Upcoming corporate dates

Gilead Sciences announced its third-quarter reporting date on October 15, 2026.
Gilead Sciences stock trades in weekend trading at Lang & Schwarz at EUR 139.28 at 5:52 p.m. CEST on October 18, 2026, 0.32 percent above the Xetra close of October 16, 2026.
The next Xetra session is scheduled for October 19, 2026.
Gilead Sciences plans to release third-quarter results on October 29, 2026.

Aquarell der Foster City Skyline mit Biotech-Campus von Gilead Sciences am Wasser — Gilead Sciences Aquarell US3755581036 Skyline Foster City Biotech-Büropark mit Segelbooten am Morgen, Illustration mit AI erstellt.

Gilead Sciences stock is at EUR 139.28 in weekend trading at Lang & Schwarz at 5:52 p.m. CEST on October 18, 2026. The price is 0.32 percent above the Xetra close of EUR 138.84 on October 16, 2026. Market context: Market report S&P 500.

Weekend trading

The quote is based on trading at Lang & Schwarz while Xetra and the primary exchanges are closed. The bid was EUR 139.14 and the ask was EUR 139.42. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.

The week in figures

Gilead Sciences was quoted at EUR 139.28 in weekend trading on October 18, 2026. The reference level is the Xetra close of EUR 138.84 on October 16, 2026, putting the weekend quote 0.32 percent higher.

Chronology of the week

On October 15, 2026, Gilead Sciences announced that it will release its third-quarter 2026 financial results after the market closes on October 29, 2026. Management is scheduled to host a webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update, according to Business Wire.

A Vir Biotechnology filing dated October 14, 2026, reported that Gilead agreed to purchase 1,765,486 Vir shares at USD 14.16 per share for an aggregate purchase price of approximately USD 25 million, subject to customary closing conditions. The filing also described a collaboration covering three PRO-XTEN dual-masked T-cell engager development candidates, as reported in the SEC filing.

Dates of the coming week

The next Xetra session is scheduled for October 19, 2026. Gilead Sciences' third-quarter 2026 results are scheduled for October 29, 2026, after the market closes, with a management webcast at 4:30 p.m. Eastern Time.